Prolong Pharmaceuticals

Prolong Pharmaceuticals is a biopharmaceutical company whose core technology is an FDA-approved delivery system for protein-based biopharmaceuticals, known as PEGylation. This process involves the chemical attachment of polyethylene glycol (“PEG”) to a therapeutic protein. The result is a product that has significantly improved therapeutic properties, affords better patient compliance and reduced side effects. Prolong seeks to develop long-acting biopharmaceuticals through its own research and by collaboration to be sold by the company or licensed to third parties in other geographic areas.